{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:00Z","timestamp":1792012320374,"version":"4.4.0"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T00:00:00Z","timestamp":1405900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"NIH\/NCI","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:p>Despite being considered \u201cgood\u2010risk\u201d acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG\u2010GO) as front\u2010line therapy of patients with CBF AML. Forty\u2010five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG\u2010GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML. Am. J. Hematol. 89:964\u2013968, 2014. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23795","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T09:58:41Z","timestamp":1404295121000},"page":"964-968","source":"Crossref","is-referenced-by-count":86,"title":["Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG\u2010GO) as front\u2010line regimen in patients with core binding factor acute myelogenous leukemia"],"prefix":"10.1002","volume":"89","author":[{"given":"Gautam","family":"Borthakur","sequence":"first","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu E.","family":"Estey","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Washington School of Medicine Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan Mahendra","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Hematopathology MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[{"name":"Department of Hematopathology MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Koller","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Brandt","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3767"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.012"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.15.610"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06276.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241075"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309149122"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23927"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4874"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402677"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4310"},{"key":"e_1_2_5_13_1","first-page":"6","article-title":"Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event\u2010free and overall survival in newly\u2010diagnosed de novo AML patients aged 50\u201370 years old: A prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA)","volume":"118","author":"Castaigne S","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05666.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_5_17_1","first-page":"76","article-title":"[Acute minimal differentiated myeloid leukemia: Report of three cases]","volume":"11","author":"Bai Y","year":"2009","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"e_1_2_5_18_1","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_5_19_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc B"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_5_21_1","first-page":"6552","article-title":"Effect of front\u2010line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG\u2010GO) on outcome in core\u2010binding factor associated acute myelogenous leukemia (CBF\u2010AML)","volume":"28","author":"Borthakur G","year":"2010","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.229"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6130"},{"key":"e_1_2_5_24_1","first-page":"484","article-title":"Attempts to optimise induction and consolidation chemotherapy in patients with acute myeloid leukaemia: Results of the MRC AML15 trial","volume":"114","author":"Burnett AK","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3640"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.06.003"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.9500"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08035.x"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403870"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435669"},{"key":"e_1_2_5_31_1","first-page":"419","article-title":"Mutations in a large cohort of young adult patients with core binding factor acute myeloid leukemia: Impact on outcome and the selection of patients for alternative treatment including transplantation in first complete remission","volume":"118","author":"Allen CG","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462879"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23795","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T14:29:54Z","timestamp":1716906594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,21]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1002\/ajh.23795"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23795","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,21]]}}}